Somewhat Positive News Coverage Somewhat Unlikely to Impact Proteon Therapeutics (PRTO) Stock Price
News headlines about Proteon Therapeutics (NASDAQ:PRTO) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Proteon Therapeutics earned a news sentiment score of 0.06 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 44.7598465355354 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Several equities research analysts have commented on PRTO shares. Zacks Investment Research downgraded Proteon Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Cowen and Company reaffirmed a “hold” rating on shares of Proteon Therapeutics in a report on Tuesday, August 8th. HC Wainwright set a $2.00 price target on Proteon Therapeutics and gave the company a “hold” rating in a report on Wednesday, August 9th. Finally, Oppenheimer Holdings, Inc. reaffirmed a “market perform” rating on shares of Proteon Therapeutics in a report on Wednesday, August 16th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $9.00.
Proteon Therapeutics (PRTO) opened at 2.65 on Friday. The company’s market capitalization is $46.69 million. The stock’s 50 day moving average price is $1.64 and its 200-day moving average price is $1.47. Proteon Therapeutics has a one year low of $1.10 and a one year high of $11.45.
Proteon Therapeutics (NASDAQ:PRTO) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.44) by $0.11. Equities analysts forecast that Proteon Therapeutics will post ($1.52) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/10/08/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-proteon-therapeutics-prto-stock-price.html.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Stock Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related stocks with our FREE daily email newsletter.